Steven Cohen’s AbCellera Biologics ABCL Stock Holding History

Steven Cohen’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,149,325	Closed	-$4.01M	–	3925
2026 Q1	$4.01M	Buy	1,149,325 +172,818	+18%	+$622K	0.01%	1858
2025 Q4	$3.34M	Buy	+976,507	New	+$4.36M	﹤0.01%	2128
2023 Q3	–	Sell	-3,959	Closed	-$25.6K	–	2407
2023 Q2	$25.6K	Buy	+3,959	New	+$27K	﹤0.01%	1743
2021 Q4	–	Sell	-272,984	Closed	-$5.47M	–	1059
2021 Q3	$5.47M	Buy	+272,984	New	+$4.83M	0.02%	643
2021 Q1	–	Sell	-55,000	Closed	-$2.21M	–	930
2020 Q4	$2.21M	Buy	+55,000	New	+$2.52M	0.01%	715

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Steven Cohen's ABCL Position: Q2 2026 in Review

Steven Cohen sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 1,149,325 shares — an estimated $4.01M sold.

Steven Cohen first reported a position in ABCL in Q4 2020 and held it in 5 quarters. The position peaked at $5.47M in Q3 2021. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Steven Cohen reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 1,149,325 AbCellera Biologics shares in Q2 2026, an estimated $4.01M.
Steven Cohen first reported a position in AbCellera Biologics in Q4 2020 and held it in 5 quarters.
Steven Cohen's AbCellera Biologics position peaked at $5.47M in Q3 2021.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.